Non-B Cell IgG Epitope Targeting for Tumor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack a specific target for non-B cell-derived IgG, which is overexpressed in various epithelial tumors and contributes to tumor proliferation, migration, and invasion, due to unknown molecular structures and mechanisms.
Innovation Solution
Identification of the CH1 domain of non-B cell-derived IgG with N-glycosylated sialic acid modification at Asn162 as a unique epitope, and its application in developing drugs targeting epithelial tumors, including non-small cell lung cancer, intestinal cancer, and others, through binding with integrin α6β4 and sialyltransferase ST3GAL4/ST3GAL6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional B cell-derived IgG is used as a target, then conventional antibody therapy can be applied, but it cannot specifically target non-B cell-derived IgG overexpressed in epithelial tumors
Solution Approach 1:
The patent identifies a specific local structural feature (N-glycosylated sialic acid at Asn162 in the CH1 domain) of non-B cell-derived IgG that distinguishes it from conventional B cell-derived IgG. By targeting this localized glycosylation modification rather than the entire IgG molecule, the invention achieves high specificity for tumor-expressed IgG while maintaining the ability to develop various therapeutic formats (antibodies, CAR-T cells, small molecules) against this unique epitope
2Ease of manufacture
If the molecular structure and mechanism of non-B cell-derived IgG are not identified, then drug development can proceed with conventional targets, but specific drugs targeting non-B cell-derived IgG cannot be prepared
Solution Approach 1:
The patent performs preliminary identification and characterization of the non-B cell-derived IgG molecular structure (N-glycosylated sialic acid at Asn162) and its biological mechanisms (integrin α6β4 binding, sialyltransferase ST3GAL4/ST3GAL6 involvement, FAK signaling pathway activation) before drug development. This preliminary structural and mechanistic elucidation enables subsequent rational drug design and development of specific therapies, avoiding the need to proceed with unknown targets
3Productivity
If non-B cell-derived IgG is not specifically targeted, then conventional cancer therapies can be used, but tumor proliferation, migration and invasion driven by non-B cell-derived IgG cannot be effectively inhibited
Solution Approach 1:
The patent extracts and isolates the specific functional epitope (N-glycosylated sialic acid at Asn162 of CH1 domain) responsible for the tumorigenic functions of non-B cell-derived IgG. By focusing therapeutic intervention on this extracted critical epitope rather than the entire IgG molecule or using non-specific conventional therapies, the invention achieves efficient inhibition of tumor proliferation, migration and invasion while providing a clear development pathway for targeted therapies
Data Source
AI summary
IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin β4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.